Health care expert Fred Goldstein, host of the AMCP Podcast Series — Listen Up!, sits down with Susan Cantrell, AMCP CEO, to discuss the significance of the recent passage of the Pre-approval Information Exchange (PIE) Act of 2022.
In the world of health care innovation, speed matters. But when it comes to developing and deploying cutting-edge treatments and therapeutics safely, a cautious and methodical approach is vital as well. Safety matters as much as speed, but faster doesn’t always mean riskier. In her latest blog, AMCP CEO Susan Cantrell discusses the history of the Pre-approval Information Exchange (PIE) Act and how it will help patients.
Hear from a panel of experts discussing how to optimize the management of inherited blood disorders.
On Dec. 14, 2022, CMS released the Calendar Year (CY) 2024 Part C and D Policy and Technical
Proposed Rule. This proposed rule applies to Medicare Advantage (MA), Part D, Medicare cost plans,
and Programs of All-Inclusive Care for the Elderly (PACE).
Andrey Ostrovsky, MD, FAAP, and Lisa Palko, PharmD, discuss the ADHD landscape, challenges, and progress, including Akili's digital therapeutics value proposition as the first FDA-authorized prescription video game treatment.
Partnership Forum: This forum helped identify payer needs and current barriers that payer currently face regarding evidence for therapies approved through an expedited approval process. In addition, participants identified potential solutions to address evidence gaps.
On Nov.7, 2022, the Centers for Medicare & Medicaid Services (CMS) issued guidance about
the Inflation Reduction Act (IRA) changes to cost sharing requirements. The requirements are
effective April 1, 2023 for Part B drugs with prices increasing faster than inflation and July 1,
2023 for the monthly Part B cost-sharing cap for insulins.
